100.83
price down icon3.94%   -4.14
after-market Handel nachbörslich: 100.83
loading
Schlusskurs vom Vortag:
$104.97
Offen:
$105.27
24-Stunden-Volumen:
854.91K
Relative Volume:
1.35
Marktkapitalisierung:
$4.96B
Einnahmen:
$338.46M
Nettoeinkommen (Verlust:
$-310.96M
KGV:
-15.44
EPS:
-6.53
Netto-Cashflow:
$-132.82M
1W Leistung:
-9.73%
1M Leistung:
-2.77%
6M Leistung:
-2.21%
1J Leistung:
+17.27%
1-Tages-Spanne:
Value
$100.78
$105.86
1-Wochen-Bereich:
Value
$100.78
$113.98
52-Wochen-Spanne:
Value
$72.21
$139.13

Axsome Therapeutics Inc Stock (AXSM) Company Profile

Name
Firmenname
Axsome Therapeutics Inc
Name
Telefon
(212) 332-3241
Name
Adresse
ONE WORLD TRADE CENTER, 29TH FLOOR, NEW YORK
Name
Mitarbeiter
589
Name
Twitter
Name
Nächster Verdiensttermin
2025-02-18
Name
Neueste SEC-Einreichungen
Name
AXSM's Discussions on Twitter

Vergleichen Sie AXSM mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
AXSM
Axsome Therapeutics Inc
100.83 5.17B 338.46M -310.96M -132.82M -6.53
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
469.65 121.28B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
563.10 60.96B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
328.81 42.77B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
591.99 36.21B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
291.47 32.08B 3.81B -644.79M -669.77M -6.24

Axsome Therapeutics Inc Stock (AXSM) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2025-07-03 Fortgesetzt Morgan Stanley Overweight
2025-06-03 Eingeleitet Oppenheimer Outperform
2025-04-07 Eingeleitet Jefferies Buy
2025-02-11 Eingeleitet Deutsche Bank Buy
2024-12-31 Bestätigt Mizuho Outperform
2024-09-03 Eingeleitet Wells Fargo Overweight
2024-08-06 Hochstufung BofA Securities Neutral → Buy
2024-07-22 Eingeleitet Needham Buy
2024-04-29 Hochstufung Morgan Stanley Equal-Weight → Overweight
2024-03-19 Eingeleitet Robert W. Baird Outperform
2024-02-06 Eingeleitet UBS Buy
2024-01-25 Eingeleitet RBC Capital Mkts Outperform
2023-12-13 Eingeleitet Citigroup Buy
2023-08-08 Hochstufung BofA Securities Underperform → Neutral
2023-01-05 Eingeleitet Piper Sandler Neutral
2022-11-01 Eingeleitet Loop Capital Buy
2022-09-07 Fortgesetzt Mizuho Buy
2021-08-10 Herabstufung Morgan Stanley Overweight → Equal-Weight
2021-06-10 Eingeleitet Berenberg Buy
2021-01-08 Eingeleitet Jefferies Buy
2020-12-16 Eingeleitet Mizuho Buy
2020-09-29 Eingeleitet BofA Securities Underperform
2020-09-10 Eingeleitet Morgan Stanley Overweight
2020-04-28 Bestätigt H.C. Wainwright Buy
2020-04-14 Eingeleitet Cowen Outperform
2019-12-30 Bestätigt H.C. Wainwright Buy
2019-12-17 Bestätigt H.C. Wainwright Buy
2019-12-16 Bestätigt Guggenheim Buy
2019-10-16 Eingeleitet Guggenheim Buy
2019-09-18 Eingeleitet William Blair Outperform
2019-05-28 Eingeleitet SunTrust Buy
2019-05-23 Bestätigt H.C. Wainwright Buy
2019-04-08 Eingeleitet SVB Leerink Outperform
2019-03-15 Bestätigt H.C. Wainwright Buy
2016-10-03 Fortgesetzt Brean Capital Buy
2015-12-15 Eingeleitet Cantor Fitzgerald Buy
2015-12-14 Eingeleitet Ladenburg Thalmann Buy
Alle ansehen

Axsome Therapeutics Inc Aktie (AXSM) Neueste Nachrichten

pulisher
03:31 AM

How strong is Axsome Therapeutics Inc. company’s balance sheetFree Market Dynamics Reports - jammulinksnews.com

03:31 AM
pulisher
03:20 AM

What makes Axsome Therapeutics Inc. stock price move sharplyHigh-yield portfolio picks - jammulinksnews.com

03:20 AM
pulisher
02:11 AM

Published on: 2025-07-27 23:41:07 - jammulinksnews.com

02:11 AM
pulisher
10:48 AM

Is Axsome Therapeutics Inc. stock overvalued or undervaluedDynamic profit expansion - jammulinksnews.com

10:48 AM
pulisher
09:51 AM

When is Axsome Therapeutics Inc. stock expected to show significant growth - jammulinksnews.com

09:51 AM
pulisher
08:35 AM

What catalysts could drive Axsome Therapeutics Inc. stock higher in 2025Unprecedented profit potential - jammulinksnews.com

08:35 AM
pulisher
08:34 AM

How does Axsome Therapeutics Inc. generate profit in a changing economyUnprecedented profit potential - jammulinksnews.com

08:34 AM
pulisher
06:58 AM

Axsome Therapeutics, Inc. (NASDAQ:AXSM) Shares Sold by Knights of Columbus Asset Advisors LLC - MarketBeat

06:58 AM
pulisher
Jul 26, 2025

Q3 EPS Estimate for Axsome Therapeutics Raised by Analyst - MarketBeat

Jul 26, 2025
pulisher
Jul 25, 2025

Axsome Therapeutics: Navigating Setbacks with a Strong Pipeline and Analyst Confidence - AInvest

Jul 25, 2025
pulisher
Jul 25, 2025

Axsome: Some Recent Setbacks, Some Recent Wins — Still A Buy (NASDAQ:AXSM) - Seeking Alpha

Jul 25, 2025
pulisher
Jul 25, 2025

Axsome Therapeutics (NASDAQ:AXSM) Shares Down 5.6%Here's Why - MarketBeat

Jul 25, 2025
pulisher
Jul 25, 2025

Axsome Therapeutics Hosts Frontiers in Brain Health R&D Day Reviewing Industry-Leading Late-Stage CNS Pipeline - ADVFN Brasil

Jul 25, 2025
pulisher
Jul 25, 2025

Why Axsome Therapeutics Inc. stock is on top investor watchlistsSuperior stock selection - jammulinksnews.com

Jul 25, 2025
pulisher
Jul 25, 2025

What analysts say about Axsome Therapeutics Inc. stockOutstanding capital growth - Autocar Professional

Jul 25, 2025
pulisher
Jul 25, 2025

Axsome Therapeutics Inc. Stock Analysis and ForecastRapid growth trajectories - PrintWeekIndia

Jul 25, 2025
pulisher
Jul 25, 2025

Axsome Therapeutics, Inc. (NASDAQ:AXSM) Stake Raised by Nationale Nederlanden Powszechne Towarzystwo Emerytalne S.A. - MarketBeat

Jul 25, 2025
pulisher
Jul 24, 2025

RBC Capital Sticks to Their Buy Rating for Axsome Therapeutics (AXSM) - The Globe and Mail

Jul 24, 2025
pulisher
Jul 24, 2025

New York State Common Retirement Fund Has $3.92 Million Position in Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat

Jul 24, 2025
pulisher
Jul 24, 2025

Is Axsome Therapeutics Inc. stock overhyped or has real potentialUnstoppable trading performance - jammulinksnews.com

Jul 24, 2025
pulisher
Jul 24, 2025

How high can Axsome Therapeutics Inc. stock price go in 2025Breakthrough investment results - jammulinksnews.com

Jul 24, 2025
pulisher
Jul 24, 2025

How To Trade (AXSM) - news.stocktradersdaily.com

Jul 24, 2025
pulisher
Jul 24, 2025

Y Intercept Hong Kong Ltd Invests $1.49 Million in Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat

Jul 24, 2025
pulisher
Jul 24, 2025

Is This Stock a Buy After Soaring by 20% in 1 Day? - AOL.com

Jul 24, 2025
pulisher
Jul 24, 2025

2 Top Stocks I Wouldn't Hesitate to Invest $1,000 in Right Now - MSN

Jul 24, 2025
pulisher
Jul 24, 2025

Legato Capital Management LLC Buys New Holdings in Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat

Jul 24, 2025
pulisher
Jul 24, 2025

Is Axsome Therapeutics Inc. a good long term investmentGame-changing returns - Autocar Professional

Jul 24, 2025
pulisher
Jul 23, 2025

Leerink Partners Keeps Bullish Stance on Axsome Therapeutics with Buy Rating - AInvest

Jul 23, 2025
pulisher
Jul 23, 2025

Lindbrook Capital LLC Cuts Holdings in Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat

Jul 23, 2025
pulisher
Jul 23, 2025

Optimistic Outlook for Axsome Therapeutics: Promising Pipeline and Potential Sales Growth Drive Buy Rating - TipRanks

Jul 23, 2025
pulisher
Jul 22, 2025

Axsome Therapeutics Breaks Below 200-Day Moving AverageNotable for AXSM - Nasdaq

Jul 22, 2025
pulisher
Jul 22, 2025

What drives Axsome Therapeutics Inc. stock priceUnprecedented profit potential - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 22, 2025

Readystate Asset Management LP Invests $6.95 Million in Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat

Jul 22, 2025
pulisher
Jul 22, 2025

ALKS Down Despite Positive Top-Line Data From Narcolepsy Study - The Globe and Mail

Jul 22, 2025
pulisher
Jul 22, 2025

Axsome Therapeutics stock rating reiterated by Cantor Fitzgerald - Investing.com Canada

Jul 22, 2025
pulisher
Jul 22, 2025

Mizuho reiterates Outperform rating on Axsome Therapeutics stock By Investing.com - Investing.com South Africa

Jul 22, 2025
pulisher
Jul 22, 2025

Axsome Therapeutics: Promising Growth Driven by Robust Pipeline and Strategic Fit - TipRanks

Jul 22, 2025
pulisher
Jul 21, 2025

Axsome Therapeutics Rings the Nasdaq Stock Market Opening Bell - Nasdaq

Jul 21, 2025
pulisher
Jul 21, 2025

Axsome Therapeutics Rings the Opening Bell - Nasdaq

Jul 21, 2025
pulisher
Jul 21, 2025

Axsome Therapeutics hosts frontiers in Brain Health R&D Day - TipRanks

Jul 21, 2025
pulisher
Jul 21, 2025

Axsome Therapeutics: A CNS Pipeline with High-Impact Catalysts for Long-Term Growth - AInvest

Jul 21, 2025
pulisher
Jul 21, 2025

Axsome Therapeutics Hosts R&D Day to Present Comprehensive Data on CNS Pipeline Targeting Alzheimer’s Disease, Depression, Narcolepsy, Fibromyalgia, ADHD, and Smoking Cessation - Nasdaq

Jul 21, 2025
pulisher
Jul 21, 2025

Axsome Reveals New Phase 3 Data for 6 Major Brain Disorders: Expert Panel Discusses Breakthrough Treatments - Stock Titan

Jul 21, 2025
pulisher
Jul 21, 2025

Axsome Therapeutics to Ring the NASDAQ Stock Market Opening Bell Today - Lelezard

Jul 21, 2025
pulisher
Jul 21, 2025

Axsome Celebrates New CNS Drug Launch with NASDAQ Bell Ringing, Unveils Brain Health Pipeline - Stock Titan

Jul 21, 2025

Finanzdaten der Axsome Therapeutics Inc-Aktie (AXSM)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$23.40
price down icon 0.97%
$36.67
price up icon 0.22%
$103.95
price up icon 0.42%
$28.67
price up icon 3.99%
$115.31
price up icon 0.65%
biotechnology ONC
$291.47
price down icon 1.68%
Kapitalisierung:     |  Volumen (24h):